Welcome to our dedicated page for Arcturus Therape news (Ticker: ARCT), a resource for investors and traders seeking the latest updates and insights on Arcturus Therape stock.
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) is a San Diego-based commercial mRNA medicines and vaccines company focused on liver and respiratory rare disease therapeutics and infectious disease vaccines. News about Arcturus often centers on clinical trial progress, regulatory interactions and collaboration updates linked to its LUNAR® lipid-mediated delivery and STARR® self-amplifying mRNA (sa-mRNA) platforms.
Investors following ARCT news can expect regular updates on the companys RNA therapeutic candidates for ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), including interim data from Phase 1 and Phase 2 studies, safety and tolerability findings, biomarker changes and plans for longer-duration or pivotal trials. Disclosures have highlighted programs such as ARCT-032, an inhaled mRNA therapy for CF, and ARCT-810, an mRNA therapeutic candidate for OTC deficiency.
Arcturus also issues frequent announcements related to its infectious disease vaccine portfolio. These include developments for KOSTAIVE®, described as the first approved self-amplifying mRNA COVID-19 vaccine, along with sa-mRNA influenza candidates like ARCT-2138 and pandemic influenza A H5N1 candidate ARCT-2304. News items may cover Phase 1 or Phase 3 data, immunogenicity and safety results, and regulatory submissions or approvals in collaboration with CSL Seqirus and partners such as Meiji Seika Pharma.
Additional ARCT headlines often involve financial results, cash runway commentary, cost management actions, investor conference participation and SEC filings that provide corporate updates. Stock Titans ARCT news page aggregates these company press releases, regulatory disclosures and related coverage so readers can track how Arcturus clinical, regulatory and partnership milestones may influence sentiment around ARCT stock over time.
Arcturus Therapeutics (NASDAQ:ARCT) reported Q2 2025 financial results and pipeline updates. Key highlights include: Q2 revenue of $28.3M (down from $49.9M in Q2 2024) and net loss of $9.2M ($0.34 per share). The company maintains a strong cash position of $253.4M, extending runway into 2028.
Pipeline progress includes: Cystic fibrosis (ARCT-032) Phase 2 interim data from nine participants expected September 2025; OTC deficiency (ARCT-810) showed positive Phase 2 results with Phase 3 planning in H1 2026; KOSTAIVE® regulatory submissions advancing globally; and Seasonal flu vaccine (ARCT-2138) demonstrated positive Phase 1 results in both young and older adults.
Arcturus Therapeutics (NASDAQ:ARCT), a commercial mRNA medicines company specializing in infectious disease vaccines and rare diseases, has scheduled its second quarter 2025 financial results announcement. The company will release its Q2 results on Monday, August 11, 2025, after market close.
A conference call and webcast will follow at 4:30 PM Eastern Time the same day. Investors can access the call via domestic (1-800-274-8461) or international (1-203-518-9814) numbers using the conference ID "ARCTURUS".
Arcturus Therapeutics (NASDAQ:ARCT), a commercial mRNA medicines company specializing in infectious disease vaccines and rare diseases, has announced its participation in two upcoming investor conferences.
The company will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on July 29, 2025, at 12:40 p.m. ET, and deliver a presentation at the CG 45th Annual Growth Conference on August 12, 2025, at 8:30 a.m. ET.
Summary not available.
Arcturus Therapeutics (Nasdaq: ARCT), a commercial mRNA medicine company specializing in infectious disease vaccines and liver and respiratory rare diseases, has announced its participation in two upcoming investor conferences in June 2025:
- Jefferies Global Healthcare Conference: Presentation scheduled for Wednesday, June 4, 2025, at 4:20 p.m. ET
- Goldman Sachs Annual Global Healthcare Conference: Fireside Chat scheduled for Monday, June 9, 2025, at 3:20 p.m. ET
Arcturus Therapeutics (Nasdaq: ARCT), a commercial messenger RNA medicines company specializing in infectious disease vaccines and liver and respiratory rare diseases, has scheduled its first quarter 2025 financial results announcement. The company will release its financial results for the quarter ended March 31, 2025, after market close on Monday, May 12, 2025.
A conference call and webcast will follow at 4:30 PM Eastern Time on the same day. Investors can access the call through domestic (1-800-267-6316) or international (1-203-518-9783) lines using the Conference ID: ARCTURUS.
Arcturus Therapeutics (Nasdaq: ARCT) has received Fast Track Designation from the U.S. FDA for its self-amplifying mRNA vaccine candidate ARCT-2304, targeting pandemic influenza A virus H5N1. The designation, granted for vaccines addressing serious conditions, will expedite the development and review process through enhanced FDA communication, priority review eligibility, and potential rolling review.
The Phase 1 clinical study for ARCT-2304 commenced in November 2024. The vaccine utilizes Arcturus' proprietary STARR® technology platform for next-generation mRNA vaccines. The project is fully supported by federal funds from the Department of Health and Human Services, specifically through BARDA under contract number 75A50122C0007.
Arcturus Therapeutics (ARCT) reported Q4 2024 financial results and pipeline updates. The company announced Phase 2 interim data for ARCT-032 (Cystic Fibrosis) and ARCT-810 (OTC deficiency) expected in Q2 2025. Q4 2024 revenues were $22.8M, down from $30.9M in Q4 2023, with a net loss of $30.0M ($1.11 per share).
Key highlights include European Commission approval for KOSTAIVE, the first approved sa-mRNA COVID-19 vaccine, and MHLW approval for commercial manufacturing in Japan. The company reported $293.9M in cash and equivalents as of December 31, 2024, with an expected runway until Q1 2027. KOSTAIVE generated approximately $28.0M in gross profit share, currently being credited against program costs.
Full-year 2024 results showed revenues of $152.3M (down from $166.8M in 2023) and a net loss of $80.9M ($3.00 per share). R&D expenses increased to $195.2M, primarily due to higher clinical trial costs for OTC, CF, COVID-19, and LUNAR-FLU programs.